Lucentis to be made available to all in England and Wales

Article

Lucentis (ranibizumab; Novartis) is to be made available to all patients of the National Health Service (NHS) in England and Wales, according to a report from the BBC. The final appraisal document (FAD) has been published ahead of final guidance, expected in June 2008.

Lucentis (ranibizumab; Novartis) is to be made available to all patients of the National Health Service (NHS) in England and Wales, according to a report from the BBC. The final appraisal document (FAD) has been published ahead of final guidance, expected in June 2008.

Previously, Lucentis was available through the NHS only to treat wet age-related macular degeneration (AMD) in a second eye following AMD-induced blindness in the first, but strong opposition by the public and the industry to this recommendation caused Britain's National Institute for Health and Clinical Excellence (NICE) to review the decision. Although NICE issued revised guidance in December 2007 recommending Lucentis be available for patients with wet AMD in either eye, many primary care trusts (PCTs) continued to follow the initial guidance.

Although already fully available in Scotland, the FAD assures that the injection will now be made available in all PCTs throughout Britain. Following final guidance, the NHS will fund the initial 14 treatments for each eye, with Novartis covering the cost of any further injections under a "dose-capping" scheme. A course of 14 injections spanning two years costs around £10,700.

The newly published FAD recommends Lucentis for the treatment of all eyes with wet AMD and best corrected visual acuity between 6/12 and 6/96.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.